NK-92
LIVE

Serial Number

87701224

Owner

NANTKWEST, INC.

Attorney

Alicia M. Passerin

Filing Date

Nov 29, 2017

Add to watchlist:

No watchlists yet
View on USPTO

NK-92 Trademark

Serial Number: 87701224 • Registration: 5512531

NK-92 is a trademark filed by NANTKWEST, INC. on November 29, 2017. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

NANTKWEST, INC. (26 trademarks)

2533 SOUTH COAST HIGHWAY 101 STE. 210
CARDIFF-BY-THE-SEA, CA 920072133

Entity Type: 03

IMMUNITYBIO, INC. (142 trademarks)

3530 JOHN HOPKINS COURT
SAN DIEGO, CA 92121

Entity Type: 03

Trademark Details

Filing Date

November 29, 2017

Registration Date

July 10, 2018

Published for Opposition

April 24, 2018

Goods & Services

[ Cells for clinical, medical, veterinary, and therapeutic purposes; cell-derived preparations, namely, natural killer cell-derived preparations, for clinical, medical, veterinary, and therapeutic purposes; therapeutic products derived from cells, namely, natural killer cells, for clinical, medical, veterinary, and therapeutic purposes; therapeutic products derived from cell-derived preparations, namely, natural killer cell-derived preparations, for clinical, medical, veterinary, and therapeutic purposes; Kits comprised of cells, reagents and related instructions, for clinical, medicinal, veterinary, and therapeutic purposes; kits comprised of cell-derived preparations, namely, natural killer cell-derived preparations, reagents and related instructions, for clinical, medicinal, veterinary, and therapeutic purposes ]

Cells for scientific, laboratory, medical, clinical, therapeutic, and diagnostic research; cell-derived preparations, namely, natural killer cell-derived preparations, for scientific, laboratory, medical, clinical, therapeutic, and diagnostic research; Kits comprised of cells, reagents and related instructions, for clinical, medicinal, and therapeutic research purposes; kits comprised of cell-derived preparations, namely, natural killer cell-derived preparations, reagents and related instructions, for clinical, medicinal, and therapeutic research purposes

Research in the field of cancer; product development in the fields of science, medicine, pharmaceuticals, veterinary medicine, therapeutics and research related thereto

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Aug 16, 2025 NA85
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Aug 16, 2025 C15P
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
May 15, 2025 EROP
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
Nov 20, 2024 PR23
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 20, 2024 APRE
TEAS SECTION 8 & 15 RECEIVED
Jun 6, 2024 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jul 10, 2023 REM1
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jun 9, 2021 ASGN
REGISTERED-PRINCIPAL REGISTER
Jul 10, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 24, 2018 NPUB
PUBLISHED FOR OPPOSITION
Apr 24, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 4, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 20, 2018 CNSA
ASSIGNED TO EXAMINER
Mar 13, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 9, 2017 NWOS
NEW APPLICATION ENTERED
Dec 2, 2017 NWAP